Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy.

Cancer chemotherapy and pharmacology - 1 Jul 2018

Yu Qianqian, Zhang Tao, Xie Conghua, Qiu Hong, Liu Bo, Huang Liu, Peng Ping, Feng Jueping, Chen Jigui, Zang Aihua, Yuan Xianglin

Abstract excerpt

PURPOSE: To investigate the association between UDP-glucuronosyltransferase (UGT)1A polymorphisms and irinotecan-treatment efficacy in a Chinese population with metastatic colorectal cancer (mCRC). METHODS: The present study was based on a prospective multicenter trial of Chinese mCRC patients treated with irinotecan-based chemotherapy (NCT01282658, registered at http://www.clinicaltrials.gov ). Fifteen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Fluorouracil

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Leucovorin

Share to Survival Rate

Source

Identifiers

PMID: 29728798
DOI: 10.1007/s00280-018-3595-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy.PMID 29728798Read ↗

Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancerSemantic proximity Read ↗

Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.Semantic proximity Read ↗

UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer.Semantic proximity Read ↗

Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.Semantic proximity Read ↗

Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer：a study from Guangxi ZhuangSemantic proximity Read ↗

UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis.Semantic proximity Read ↗

Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.Semantic proximity Read ↗

Correlation between UGT1A1 polymorphism and efficacy and toxicity of irinotecan in Chinese cancer patientsSemantic proximity Read ↗

UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.Semantic proximity Read ↗

UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.Semantic proximity Read ↗

Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.Semantic proximity Read ↗

UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.